Last reviewed · How we verify
NCT05177666
a Prospective Registration Study for Patients With Advanced Refractory Solid Tumors
trial testing Targeted therapy in Feasibility in 120 participants. Status unknown.
30 December 2023
Quick facts
| Lead sponsor | The University of Hong Kong-Shenzhen Hospital |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 120 |
| Start date | 30 December 2021 |
| Primary completion | 30 December 2023 |
| Estimated completion | 30 March 2024 |
Drugs / interventions tested
- Targeted therapy — full drug profile →
Conditions studied
- Feasibility — all drugs for Feasibility →
- Effectiveness — all drugs for Effectiveness →
- Safety — all drugs for Safety →
- Targeted Molecular Therapy — all drugs for Targeted Molecular Therapy →
Sponsor
The University of Hong Kong-Shenzhen Hospital
Who can join
18 and older, any sex, with Feasibility or Effectiveness. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a prospective registration study for patients with advanced refractory solid tumors. Patients who meet the eligibility criteria will be included to participate in the study, and baseline information to be collected after signed informed consent. Patients will choose for themselves whether to carry out targeted therapy or other appropriate treatment methods. And we plan to follow up for at least 12 months or until disease progression or death.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05177666
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Targeted therapy
Trials testing the same drug.
- NCT06521866 — Phase II Study of Serplulimab Combined with First-Line Targeted Therapy, Chemotherapy, and Radiation in Advanced Colorec · Phase 2 · recruiting
- NCT06249750 — Clinical Application of Near-infrared Whole Body Heat Shock Multimodal Technique in Treatment of Castration-resistant Pr · Phase 2 · recruiting
- NCT05535998 — TACE-HAIC Combined With TKIs and Immunotherapy Versus TACE Alone for Hepatocellular Carcinoma With PVTT · completed
- NCT04807127 — A Single-cell Approach to Identify Biomarkers of Pulmonary Toxicity for Immune Checkpoint Blockade · recruiting
- NCT02745691 — Psychometric Properties of the EORTC QLQ-LC29 · completed
Other recruiting trials for Feasibility
Currently open trials in the same condition.
- NCT07194902 — HIV Self-testing for Partners of HIV-uninfected Postpartum Women · NA · recruiting
- NCT06322199 — Differences Between Suicide Attempters and Suicide Ideators. Influence of the Brief Therapy Attempted Suicide Short Inte · active not recruiting
Other The University of Hong Kong-Shenzhen Hospital trials
Trials by the same sponsor.
- NCT07013461 — International Collaborative Study on AJCC/UICC TNM-10 for Nasopharyngeal Cancer · not yet recruiting
- NCT07050706 — The Correlation Between Serum PRMT5 Level and Cardiac Ultrasound Indicators in Patients With Heart Failure · enrolling by invitation
- NCT07015554 — Serum IGF1 on Female HFpEF Patients · enrolling by invitation
- NCT06314087 — Individualized Neoantigen Therapy with Unusual Radiotherapy Enhancement (iNATURE) · Phase 2 · recruiting
- NCT06593223 — Non-invasive Filling Pressure(NIFP) Device Based on Low Frequency Heart Sound in Assessment of Congestion in Heart Failu · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05177666 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by The University of Hong Kong-Shenzhen Hospital
- Last refreshed: 4 January 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05177666.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing